Industrials

RICHMOND, Va., July 16, 2025 (GLOBE NEWSWIRE) -- The Brink’s Company (NYSE:BCO), a leading global provider of cash and valuables management, digital retail solutions, and ATM managed services, will host a conference call on Wednesday, August 6, at 9:00 a.m. (EDT) to review second-quarter financial results, which will be released earlier that morning.

TEL AVIV, Israel, July 16, 2025 (GLOBE NEWSWIRE) -- Gauzy Ltd. (Nasdaq: GAUZ) (“Gauzy” or the “Company”), a global leader in vision and light control technologies, today announced it will release financial results for the second quarter ended June 30, 2025, before the market opens on Wednesday, August 13, 2025. Management will host a webcast and conference call at 8:30 a.m. EDT on the same day to review results.

As previously announced on July 8, 2025, the upcoming reverse share split could not be carried out due to unforeseen technical issues beyond Fingerprint Cards AB’s (publ) (“FPC” or the “Company”) control and the Company withdrew the resolution for the record date planned to be held on July 11, 2025.

The recommerce market in Asia Pacific is set for notable growth, reaching USD 77.5 billion by 2025, with a robust CAGR of 11.6%. The market's expansion, featuring key segments like electronics and fashion, is driven by digital adoption and sustainable practices. Get insights on market dynamics and opportunities with our 13-region report.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Ultomiris Drug Market size & share revenue was valued at approximately USD 4.16 Billion in 2024 and is expected to reach USD 5.47 Billion in 2025 and is expected to reach around USD 64.12 Billion by 2034, at a CAGR of 31.52% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are AstraZeneca, Xencor, Inc., Chugai Pharmaceutical, Argenx, Alexion Pharmaceuticals, and others.